CRISPR Therapeutics AG (CRSP)
53.90
+0.17
(+0.32%)
USD |
NASDAQ |
Apr 26, 16:00
53.89
-0.01
(-0.02%)
After-Hours: 20:00
CRISPR Therapeutics Cash from Operations (TTM): -260.38M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -260.38M |
| September 30, 2023 | -277.63M |
| June 30, 2023 | -342.99M |
| March 31, 2023 | -351.70M |
| December 31, 2022 | -495.74M |
| September 30, 2022 | -468.45M |
| June 30, 2022 | -444.56M |
| March 31, 2022 | 504.40M |
| December 31, 2021 | 538.97M |
| September 30, 2021 | 543.80M |
| June 30, 2021 | 549.43M |
| March 31, 2021 | -286.85M |
| December 31, 2020 | -238.37M |
| September 30, 2020 | -153.78M |
| June 30, 2020 | 55.34M |
| Date | Value |
|---|---|
| March 31, 2020 | 48.24M |
| December 31, 2019 | 56.68M |
| September 30, 2019 | 24.93M |
| June 30, 2019 | -128.46M |
| March 31, 2019 | -117.29M |
| December 31, 2018 | -96.24M |
| September 30, 2018 | -82.71M |
| June 30, 2018 | -78.61M |
| March 31, 2018 | -69.37M |
| December 31, 2017 | -70.09M |
| September 30, 2017 | -72.22M |
| June 30, 2017 | -68.62M |
| March 31, 2017 | -66.26M |
| December 31, 2016 | -52.86M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-495.74M
Minimum
Dec 2022
549.43M
Maximum
Jun 2021
-59.32M
Average
-153.78M
Median
Sep 2020
Cash from Operations (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 3.537B |
| Intellia Therapeutics Inc | -394.09M |
| Novartis AG | 13.77B |
| Verve Therapeutics Inc | -149.55M |
| AC Immune SA | -67.27M |